title: Are low doses of enoxaparin with aspirin sufficient to guarantee good gestational outcome in women with heterozygote factor V Leiden mutation?
authors.forename: K
authors.initials: K
authors.lastname: Monastiri
authors.forename: B
authors.initials: B
authors.lastname: Seket
authors.forename: S
authors.initials: S
authors.lastname: Chouchane
authors.forename: M M
authors.initials: MM
authors.lastname: Samama
authors.forename: T
authors.initials: T
authors.lastname: Mahjoub
mesh_terms: D000022:Abortion, Spontaneous / Q000517:prevention & control*; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000627:therapeutic use*; D005165:Factor V / Q000187:drug effects* / Q000235:genetics; D005260:Female; D006579:Heterozygote; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D010975:Platelet Aggregation Inhibitors; C095381:factor V Leiden; D005165:Factor V; D001241:Aspirin